Brookstone Capital Management Buys 17,237 Shares of Johnson & Johnson (NYSE:JNJ)

Brookstone Capital Management raised its position in Johnson & Johnson (NYSE:JNJ) by 24.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 86,516 shares of the company’s stock after purchasing an additional 17,237 shares during the quarter. Brookstone Capital Management’s holdings in Johnson & Johnson were worth $13,686,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Keener Financial Planning LLC bought a new stake in Johnson & Johnson in the 4th quarter valued at approximately $40,000. WFA Asset Management Corp raised its holdings in shares of Johnson & Johnson by 61.4% in the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after purchasing an additional 97 shares during the last quarter. Vermillion & White Wealth Management Group LLC acquired a new position in Johnson & Johnson during the fourth quarter worth $44,000. Disciplined Equity Management Inc. bought a new position in Johnson & Johnson in the fourth quarter valued at $45,000. Finally, Grayhawk Investment Strategies Inc. increased its stake in Johnson & Johnson by 528.6% in the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after buying an additional 259 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

JNJ has been the subject of several analyst reports. Royal Bank of Canada restated an “outperform” rating and issued a $175.00 price objective on shares of Johnson & Johnson in a report on Monday, June 17th. Morgan Stanley lowered their price target on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 17th. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and increased their price objective for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Thursday, June 20th. Finally, Bank of America cut their price target on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Eight analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $174.07.

Johnson & Johnson Stock Down 0.3 %

Johnson & Johnson stock opened at $146.81 on Thursday. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $175.97. The stock has a market cap of $353.32 billion, a P/E ratio of 9.15, a P/E/G ratio of 2.45 and a beta of 0.53. The company’s 50-day moving average price is $148.13 and its two-hundred day moving average price is $154.24. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.64 by $0.07. The business had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The firm’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period last year, the firm posted $2.68 EPS. As a group, analysts expect that Johnson & Johnson will post 10.63 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st were paid a $1.24 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date was Monday, May 20th. This represents a $4.96 annualized dividend and a yield of 3.38%. Johnson & Johnson’s payout ratio is 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.